Benitec Biopharma (NASDAQ:BNTC) Research Coverage Started at Raymond James Financial

Raymond James Financial assumed coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a report issued on Friday morning, Marketbeat.com reports. The firm issued an outperform rating and a $14.00 price objective on the biotechnology company’s stock.

A number of other research analysts also recently weighed in on the stock. Royal Bank Of Canada upgraded shares of Benitec Biopharma to an “outperform” rating in a research report on Tuesday, September 15th. Wedbush lifted their price target on Benitec Biopharma from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Thursday, October 15th. Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Benitec Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Benitec Biopharma Stock Performance

Benitec Biopharma stock opened at $8.65 on Friday. Benitec Biopharma has a fifty-two week low of $8.00 and a fifty-two week high of $16.76. The business’s 50-day simple moving average is $10.82 and its two-hundred day simple moving average is $11.69. The company has a market cap of $301.80 million, a PE ratio of -8.83 and a beta of 0.25.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). As a group, analysts predict that Benitec Biopharma will post -1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Benitec Biopharma by 18.7% during the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 1,256 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 5,251 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Benitec Biopharma in the first quarter worth approximately $186,000. Bank of New York Mellon Corp increased its position in shares of Benitec Biopharma by 37.6% during the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 11,877 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in shares of Benitec Biopharma during the second quarter worth approximately $2,515,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) technology. The platform is designed to enable cells to produce small hairpin RNA molecules that can selectively reduce the expression of disease-causing genes, potentially providing longer-lasting gene silencing than conventional RNA-based approaches.

The company’s lead program is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD1), a rare inherited disorder that affects muscles involved in swallowing and movement.